Skip to Content
US Videos

An Industry Leader Trading at a Sizable Discount

Falling crop prices and an ill-advised pursuit of Syngenta have obscured wide-moat Monsanto's growth opportunities.

Mentioned:

Jeff Stafford: We think Monsanto (MON) is the undisputed leader in seeds and genomics, which is more akin to the pharmaceutical industry than other agriculture markets. The firm has built a wide economic moat on the back of its intangible assets in seeds, both from biotech traits, which are licensed broadly to competitors, and from Monsanto's best-in-class seed-breeding operation. The company has shown the ability to raise prices, even in years when corn and soybean prices drop, primarily through introducing higher-yielding seeds and new biotech traits.

Falling crop prices and an ill-advised pursuit of Syngenta (SYT) have driven Monsanto's stock down to attractive levels. With the value-destructive Syngenta deal off the table, we think the market will eventually focus on Monsanto's ample standalone growth opportunities. Our long-term view of the company is bolstered by our forecast for caloric intake in emerging markets, which will put stress on crop-yield improvements globally and should play to Monsanto's strengths.

Jeffrey Stafford does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.